Why U.S. Generic Drug Manufacturing Is So Difficult

The United States wants to reduce its dependence on overseas pharmaceutical suppliers and produce more generic medicines domestically. The goals are straightforward: strengthen the drug supply chain, reduce shortage risks, and protect access to essential treatments during geopolitical or logistical disruptions.

The challenge is that generic-drug manufacturing involves more than building factories. It depends on low-cost inputs, reliable demand, specialized workers, regulatory capacity, quality control, and purchasing systems that reward supply security rather than price alone.

India offers a useful case study. It is one of the world’s largest producers and exporters of generic medicines. Its pharmaceutical industry demonstrates how scale, specialization, and lower operating costs can make medicines affordable. It also shows why manufacturing capacity alone cannot guarantee uninterrupted supplies or low prices.

The central lesson is clear: U.S. generic drug manufacturing could improve resilience, but only if policymakers support the entire system. Affordable inputs, diversified suppliers, strong quality standards, long-term contracts, and targeted investment matter as much as domestic factories.

Why the United States Wants More Generic Drugs Made Domestically

Generic drugs are essential to the U.S. health system

Generic medicines provide lower-cost alternatives to brand-name drugs. They help patients afford long-term treatments and allow insurers, hospitals, public programs, and pharmacies to control spending.

Generics account for most prescriptions dispensed in the United States, even though brand-name products often capture a larger share of total drug spending. A disruption involving a common generic can therefore affect millions of patients, particularly those who depend on medicines for infections, cancer treatment, surgery, chronic diseases, and emergency care.

The term “generic drug production” covers several activities:

• Finished-dose manufacturing: Producing tablets, capsules, liquids, creams, or injections for patients.
• Active pharmaceutical ingredient production: Making the chemical substance responsible for a medicine’s therapeutic effect.
• Specialized manufacturing: Producing sterile injectables, biologics, complex formulations, and other products requiring advanced facilities.

A medicine can be finished in the United States while depending on imported active ingredients, chemical precursors, packaging, or specialized equipment. Domestic production at one stage does not automatically create a fully domestic supply chain.

Foreign dependence creates supply-chain risks

The global pharmaceutical industry relies on international specialization. Companies source ingredients, manufacture products, package medicines, and distribute them across multiple countries. This system can lower costs, but it can also create vulnerabilities.

Risks include:

• Factory shutdowns
• Shipping delays
• Export restrictions
• Natural disasters
• Geopolitical tensions
• Shortages of chemical inputs
• Regulatory shutdowns
• Dependence on a single upstream supplier

Risk increases when multiple manufacturers purchase an essential ingredient from the same source. Several companies may appear to compete while relying on one factory or region for a critical input.

Low prices can conceal this fragility. When manufacturers earn little profit, they may not maintain spare capacity, duplicate equipment, or backup suppliers. The market can function efficiently under normal conditions and fail quickly during a disruption.

Tariffs and industrial policy are part of the debate

A proposal reported by Time would impose 100% tariffs on generic drugs beginning in 2028. The proposal is presented as a way to make imported medicines more expensive and encourage companies to manufacture in the United States. It should not be treated as settled policy without confirmation from authoritative government sources. Source 7

The intended logic is familiar:

1. Raise the cost of imported medicines.
2. Encourage investment in American factories.
3. Reduce dependence on foreign suppliers.
4. Create domestic capacity for critical medicines.

The policy question is whether tariffs would build capacity before they raise prices. A factory can take years to finance, construct, equip, validate, and approve. If tariffs take effect first, hospitals, insurers, government programs, and patients could face higher costs before domestic alternatives are ready.

India’s Pharmaceutical Success Offers a Complicated Lesson

India became a global generic-drug powerhouse

India developed a large pharmaceutical industry through manufacturing scale, technical expertise, export experience, and comparatively low operating costs. Indian companies produce medicines for domestic use and international markets, including the United States.

The industry includes manufacturers of active pharmaceutical ingredients, finished-dose medicines, contract products, and specialized formulations. Companies compete through high production volumes, low unit costs, international regulatory experience, and extensive distribution networks.

This model has helped expand access to affordable medicines worldwide. Indian manufacturers supply a significant share of the generic medicines used in many countries, including the United States. India’s experience is one reason policymakers often look to the country when discussing lower-cost pharmaceutical production.

But India’s success does not show that a country can simply build factories and eliminate drug shortages. The industry depends on a broader commercial and logistical system. Reports examining the American push for domestic generic production use India to illustrate the difficulty of transferring that model to a higher-cost economy. Source 1

Low prices depend on global specialization

India’s pharmaceutical model is not entirely self-contained. Manufacturers may depend on imported chemical precursors, active ingredients, excipients, packaging materials, machinery, and international freight.

Relocating finished-dose production from India to the United States may therefore fail to remove foreign dependence. A U.S. factory could still rely on imported ingredients or specialized components. The supply chain might become more expensive and geographically complex without becoming fully secure.

The same principle applies to India. A major producing country can still face disruptions if it depends on concentrated upstream sources or encounters transportation and regulatory problems.

Policymakers must ask:

• Where are active ingredients produced?
• Who supplies the chemical precursors?
• Are qualified backup manufacturers available?
• How quickly can production increase?
• Are packaging and delivery systems resilient?
• Can a factory operate during a regional crisis?

Scale does not eliminate shortages or quality problems

Large manufacturing capacity helps lower costs, but it does not guarantee reliable supply. Production interruptions, equipment failures, regulatory findings, quality-control failures, and approval delays can remove products from the market.

A quality problem at one facility can affect the wider system. Hospitals may search for replacement suppliers, pharmacies may face allocation limits, and patients may need to change treatments. Remaining manufacturers may struggle to meet sudden demand.

India’s experience offers two lessons:

• Scale and specialization can make medicines affordable.
• Scale does not replace quality assurance, regulatory oversight, or supplier diversification.

The U.S. debate should not treat India’s manufacturing volume as a simple blueprint. The conditions supporting India’s low-cost model cannot be reproduced instantly in the United States.

Why Generic-Drug Manufacturing Is Difficult to Rebuild in America

U.S. production costs are higher

American manufacturers generally face higher costs for labor, energy, land, construction, insurance, environmental compliance, waste disposal, and equipment maintenance. These expenses are especially significant for sterile injectables and other products requiring highly controlled facilities.

Generic drugs create an additional challenge. Buyers often select suppliers largely on price because the products are viewed as interchangeable. Manufacturers may operate on narrow margins even when their medicines are medically essential.

A U.S. plant may therefore cost more to operate while competing in a market that does not automatically pay more for domestic production. Without long-term purchasing commitments, companies may hesitate to invest in new facilities or maintain unused backup capacity.

Generic-drug markets reward low prices, not resilience

Procurement systems and reimbursement arrangements often reward the lowest immediate price. That can benefit patients and health programs under normal conditions, but it can discourage investment in resilience.

Possible consequences include:

• Suppliers leaving unprofitable markets
• Manufacturers delaying facility upgrades
• Production becoming concentrated among fewer companies
• Buyers failing to pay for backup capacity
• Companies sourcing from the cheapest available region

Short-term savings can create long-term risk. A low-priced medicine becomes costly when a shortage forces hospitals to purchase emergency supplies, substitute another treatment, delay care, or redesign clinical protocols.

A resilient system may require paying slightly more during normal periods to avoid much larger costs during disruptions.

Building factories takes years

Domestic capacity cannot appear immediately after a policy announcement. Manufacturers must secure financing, select a site, obtain permits, construct a facility, install equipment, recruit workers, validate production processes, and complete regulatory reviews.

The process may include:

1. Identifying a medicine and market opportunity
2. Securing financing and long-term buyers
3. Selecting and preparing a site
4. Constructing the facility
5. Installing production and quality-control equipment
6. Recruiting and training employees
7. Validating manufacturing processes
8. Completing regulatory review
9. Reaching reliable commercial-scale production

Sterile injectables and complex medicines may require particularly demanding facilities. They must meet strict standards for contamination control, environmental conditions, equipment, and testing.

This timeline creates a transition problem. Tariffs applied before domestic alternatives are ready could increase prices without producing immediate supply security.

Regulation and Quality Control Create a Necessary Trade-Off

Generic drugs must meet strict standards

Regulatory requirements protect patients by confirming a medicine’s safety, strength, purity, identity, and consistency. A generic must perform as expected and remain stable throughout its shelf life.

Manufacturing standards also reduce the risk of contamination, incorrect dosage, defective packaging, and other failures. These requirements can raise production costs, but weakening them would create new health risks and undermine confidence in domestic medicines.

Faster approvals do not solve manufacturing economics

Approving a generic drug and producing it reliably are different tasks. A manufacturer may receive approval for a product but still struggle with equipment problems, labor shortages, input-price volatility, or inadequate commercial demand.

Streamlined regulatory processes could reduce delays and help companies enter the market. They cannot eliminate construction costs, quality-control expenses, or thin profit margins.

Regulators and manufacturers need faster communication, clearer requirements, and efficient inspections while preserving standards that protect patients. Speed without quality can turn a supply problem into a safety problem.

Quality failures can remove capacity from the market

When regulators identify serious manufacturing deficiencies, a plant may face restrictions or shutdowns. That action can be necessary for patient safety, but it can also worsen shortages if few other suppliers exist.

The effects can spread through the system:

• Hospitals search for replacement suppliers.
• Pharmacies face allocation limits.
• Patients switch treatments.
• Remaining manufacturers face unexpected demand.
• Prices may rise as supply tightens.

Quality assurance is not separate from supply security. A reliable supply requires manufacturers that can produce medicines consistently and regulators that can detect and correct problems before they become widespread.

The Supply Chain Problem Extends Beyond Finished Drugs

Active ingredients may remain imported

Active pharmaceutical ingredients, or APIs, are the substances that produce a drug’s therapeutic effect. A U.S. company may manufacture tablets domestically while importing the API from another country.

Other vulnerable inputs include:

• Chemical precursors
• Excipients, which help form and stabilize medicines
• Vials and syringes
• Labels and packaging
• Filters and testing materials
• Specialized production machinery

A policy focused only on finished-dose manufacturing may create the appearance of domestic production without eliminating key foreign dependencies.

Concentration matters as much as geography

Moving a supplier from one country to another does not automatically create resilience. A single American factory can be as vulnerable as a single overseas factory if it is the only source of a medicine or ingredient.

Policymakers should measure:

• The number of qualified manufacturers
• The number of API suppliers
• Available backup capacity
• Geographic distribution
• The time required to increase production
• Inventory levels
• Dependence on shared upstream sources

A diversified international supply chain may be safer than a purely domestic system concentrated in one facility or region.

India’s model shows the benefits of specialization

India built advantages through specialization, scale, experience, and export networks. The United States may need a different strategy rather than attempting to reproduce India’s entire pharmaceutical sector.

A practical American approach could focus on:

• Essential medicines
• Drugs with repeated shortages
• Hospital injectables
• Products with few qualified suppliers
• Medicines dependent on narrow foreign inputs
• Strategic reserves
• Multiple suppliers supported by long-term contracts

The goal should be resilience where it matters most, not domestic production of every generic drug regardless of cost.

Will Tariffs Make Generic Drugs More Expensive?

The short-term price risk

A tariff raises the cost of imported medicines. Importers may pass some or all of that cost to hospitals, insurers, government programs, pharmacies, and patients.

The greatest risks may affect medicines with few suppliers, low profit margins, no immediate domestic substitute, or specialized manufacturing requirements. Hospital injectables are particularly sensitive because they require complex facilities and can be difficult to replace quickly.

A tariff could therefore produce higher prices before it generates new domestic capacity.

The long-term price argument

Supporters of tariffs may argue that domestic production would reduce exposure to international disruptions and create a more competitive American manufacturing base. If multiple U.S. suppliers eventually enter the market, competition could reduce costs and improve availability.

Those benefits depend on successful investment. Tariffs alone do not guarantee factories, trained workers, affordable inputs, or qualified suppliers. They must be paired with financing, stable purchasing commitments, infrastructure, and regulatory coordination.

The risk of unintended shortages

Suppliers facing higher costs could reduce exports, raise prices, leave the U.S. market, or delay expansion. A policy intended to improve resilience could produce shortages if implementation is too rapid.

Possible transition measures include:

• Phased tariff implementation
• Exemptions for shortage-prone medicines
• Advance purchasing commitments
• Minimum inventory requirements
• Monitoring of supplier capacity
• Temporary waivers when no domestic alternative exists

The effect of pharmaceutical tariffs would depend on timing, product coverage, exemptions, and the pace of domestic investment. Source 7

What the United States Can Learn From India

Treat supply security as a system

Policymakers should map the entire generic-drug supply chain, including raw materials, APIs, finished products, packaging, distribution, and emergency reserves.

A factory-based strategy is incomplete if a facility depends on a single foreign ingredient supplier or cannot obtain critical packaging.

Pay for reliability, not only low prices

Purchasing systems could support resilience through:

• Multi-year contracts
• Minimum-volume guarantees
• Premiums for backup capacity
• Government purchasing commitments
• Incentives for geographic diversity
• Payments for maintaining emergency inventory

These measures can make domestic investment more attractive and reduce pressure to compete only through the lowest price.

Target medicines most important to public health

The United States does not need to produce every generic domestically. It should prioritize medicines with repeated shortages, essential hospital uses, few suppliers, or highly concentrated foreign inputs.

Targeted investment is more realistic than broad protectionism. It also reduces the risk of spending large sums to reproduce capacity that already exists elsewhere.

Preserve competition and quality standards

Replacing foreign concentration with domestic concentration would not solve the problem. A resilient system needs multiple qualified suppliers, transparent inspections, strong quality systems, and public information about shortages and production capacity.

Redundancy, accountability, and affordability must operate together.

The Broader Drug-Pricing Problem

Generic competition is only one part of affordability

Generic manufacturing can reduce costs, but it cannot solve every cause of unaffordable treatment. Brand-name pricing, patent protections, insurance design, negotiating power, and distribution markups also shape what patients pay.

The International Consortium of Investigative Journalists’ reporting on Merck’s Keytruda illustrates the broader issue. The cancer drug became a major commercial success while its pricing raised questions about access for patients around the world. Source 9

Expanding U.S. generic drug production addresses supply and competition in only part of the pharmaceutical market. It does not replace policies dealing with brand-name prices, patents, insurance coverage, and patient cost sharing.

Drug access depends on both price and availability

A medicine can be affordable but unavailable during a shortage. It can also be widely available but unaffordable because of high prices or inadequate insurance coverage.

Effective policy must address both problems. Patients need medicines that are reasonably priced and reliably available.

Conclusion: More American Manufacturing, but Not at Any Cost

India shows that generic-drug manufacturing can achieve impressive scale and low prices. It also shows that the model depends on complex supply chains, strict quality controls, technical expertise, and reliable commercial incentives.

The United States should not assume that tariffs will build capacity immediately. It should not focus only on finished-dose production, weaken quality standards, or measure success by factory count alone.

Domestic manufacturing can strengthen medicine supplies when paired with long-term contracts, diversified sourcing, targeted incentives, strategic reserves, and careful regulation. The objective should be a pharmaceutical system that is resilient and affordable—not simply a more expensive system located inside the United States.

Frequently Asked Questions

Why does the United States want to produce more generic drugs domestically?

The United States wants to reduce dependence on overseas suppliers, limit shortage risks, protect access to essential medicines, and strengthen control over critical parts of the pharmaceutical supply chain.

Why is India important to the generic-drug debate?

India is one of the world’s major generic-drug producers. Its experience shows how scale and lower operating costs can support affordable medicines while demonstrating that production depends on complex global inputs, strict quality controls, and reliable commercial incentives.

Would tariffs make generic drugs more expensive?

Tariffs could raise prices in the short term if importers pass higher costs to hospitals, insurers, government programs, or patients. Long-term effects would depend on whether the policy creates competitive domestic production.

Can the United States manufacture every generic drug domestically?

Probably not at the same cost or efficiency. A practical strategy would prioritize essential medicines, shortage-prone products, and drugs with concentrated supply chains while maintaining diversified international sourcing for other products.

What is the biggest obstacle to expanding U.S. generic-drug manufacturing?

The central obstacle is economics. Generic drugs usually have low profit margins, while U.S. production involves higher labor, construction, compliance, and operating costs. Manufacturers need stable demand and long-term purchasing commitments to justify investment.

Does domestic production guarantee a secure drug supply?

No. Domestic factories can still face quality failures, equipment problems, labor shortages, raw-material disruptions, or insufficient capacity. True supply security requires multiple qualified suppliers, backup capacity, strong oversight, and visibility across the full supply chain.